Janet Huang

Ultivue, Inc. engages in provision of biotechnology services. It offers super-resolution imaging, single-molecule and diagnostics services. Its product Multiplex IHC Reagent Kits, a performance marker multiplexing detection and analysis.The company was founded by Peng Yin, David Walt and Ralf Jumgmann in 2015 and is headquartered in Cambridge, MA.

Torus Biosystems, Inc. engages in the provision of biotechnology services. It performs DNA testing for scientific and medical research purposes. The company was founded in 2019 and is headquartered in Brookline, MA.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA.

Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China.

Silicon Therapeutics LLC operates as an integrated computational drug discovery company that focuses on developing novel medicines for diseases. Its INSITE platform closely represents the dynamical nature of targets using all-atom simulations. The firm has offices in Boston and Shanghai. The company was founded by Lijun Sun, Peiqi Sun, Elliot L. Chaikof, and Finith Jernigan, III in 2016 and is headquartered in Boston, MA.

Wuhan Neurophth Biotechnology Co., Ltd. is a leading in-vivo gene therapy company for ophthalmic diseases based in Wuhan, China. The Chinese company's core product, nr082 (nfs-01), is designed to treat ND4-mediated Leber's hereditary optic neuropathy (ND4-LHON) and has been granted orphan drug designation (ODD) by the FDA and EMA. It is the first Chinese gene therapy new drug that has been granted IND approval for clinical trials by the Chinese National Medical Products Administration (NMPA) and the FDA. The company's pipeline also includes ND1-mediated LHON, autosomal dominant optic atrophy, optic nerve protection, vascular retinopathy, and other preclinical candidates. The company was founded in 2016 by Bin Li, Su Xiao, Dabo Cai, and Bin Li has been the CEO since then.

Shenzhen Jingtai Technology Co., Ltd. is a company that researches and develops biotechnology products. The company is based in Shenzhen, China. The Chinese company was founded in 2015 by Shu Hao Wen, Jian Ma, Li Peng Lai. Jian Ma has been the CEO since 2015.

Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin.

CarrierGene Biotech Co., Ltd. engages in the identification of the causes of infertility for patients through genetic testing technology and data analysis algorithms. The company was founded in 2016 and is headquartered in Suzhou, China.